Premium
Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
Author(s) -
Romiti R.,
Valenzuela F.,
Chouela E.N.,
Xu W.,
Pangallo B.,
Moriarty S.R.,
Gürbüz S.,
Riedl E.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.17604
Subject(s) - ixekizumab , medicine , psoriasis , clinical trial , latent tuberculosis , tuberculosis , plaque psoriasis , dermatology , outcome (game theory) , mycobacterium tuberculosis , psoriatic arthritis , pathology , secukinumab , mathematics , mathematical economics
Tuberculosis (TB) is one of the top ten causes of death worldwide, with approximately 10.0 million active TB cases in 2017 (range 9.0 to 11.1 million) occurring in all countries and age groups and estimates of 1.7 billion people having latent TB infection (LTBI). The lifetime risk for reactivation of LTBI is 5% to10%, and certain immunosuppressant therapies increase this risk. Data on TB risk following anti-interleukin (IL)-17A treatment in humans are limited, with no cases of LTBI reactivation reported thus far. This article is protected by copyright. All rights reserved.